Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer

Journal of Urology

Volumn 168, Issue 3, 2002, Pages 1001-1004

  Sharifi, Roohollah ^a,b   Browneller, Robert ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b TAP PHARMACEUTICAL PRODUCTS INC   (United States)

Author keywords

Leuprolide; Prostatic neoplasms; Testosterone

Indexed keywords

LEUPRORELIN; TESTOSTERONE;

ADVANCED CANCER; AGED; ARTICLE; DRUG FORMULATION; HUMAN; HUMAN TISSUE; HYPOPHYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE RELEASE; UNITED STATES;

EID: 0036718402     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)64560-0     Document Type: Article

References (8)

1. Physiological basis for hormonal therapy in carcinoma of the prostate
2. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer
3. Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer
4. Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer
5. Androgen suppression by a gonadotropin releasing hormone analogue in patients with metastatic carcinoma of the prostate
6. Can combined DES and LHRH depot therapy (ICI 118630) prevent endocrinologic and clinical flare-up in metastatic prostate cancer?
7. Zoladex (ICI 118, 630): Clinical trial of new luteinizing hormone-releasing hormone analog in metastatic prostatic carcinoma
8. Acute on chronic effect of depot Leuprolide in patients with stage D2 cancer of prostate